Peg-filgrastim

DRUG8 trials

Conditions

Aggressive B-cell Lymphoma With Secondary Involvement of the CNSBrain CancerBrain TumorBrain Tumor, PediatricBrain Tumor, RecurrentBrain Tumor, RefractoryBreast CancerCNS Cancer

Phase 1

A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

TerminatedNCT01258634

University of ChicagoLung Metastases, Osteosarcoma

Start: 2010-07-31End: 2011-11-30Updated: 2013-12-10

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

CompletedNCT02392793

St. Jude Children's Research HospitalChildhood Solid Tumors

Start: 2015-03-25End: 2019-08-30Updated: 2021-02-09

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

CompletedNCT04023669

St. Jude Children's Research HospitalBrain Cancer, Brain Tumor, Brain Tumor, Pediatric +10

Start: 2019-08-08End: 2025-01-13Updated: 2025-02-07

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruitingNCT05211336

National Cancer Institute (NCI)Aggressive B-cell Lymphoma With Secondary Involvement of the CNS, Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)

Start: 2022-04-19End: 2029-06-01Updated: 2026-01-08

Phase 2

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

Active, not recruitingNCT01783535

St. Jude Children's Research HospitalRetinoblastoma

Start: 2013-06-19End: 2028-01-31Target: 174Updated: 2024-04-16

Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

TerminatedNCT02685111

Asan Medical CenterBreast Cancer, Febrile Neutropenia, Neutropenia

Start: 2016-02-29End: 2017-12-31Updated: 2020-07-31

Phase 3

Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

NCT03404752

Gema Biotech S.A.Breast Cancer

Start: 2015-08-31End: 2018-12-31Target: 120Updated: 2018-01-19

Unknown Phase

Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN

CompletedNCT04460079

CinnagenChemotherapy-induced Neutropenia

Start: 2016-03-29End: 2019-09-07Updated: 2020-07-07

Journal of Clinical Oncology2025-05-28

MDB-65. RESULTS FROM THE SJ-ELIOT PHASE 1 CLINICAL TRIAL EVALUATING PREXASERTIB (LY2606368) IN COMBINATION WITH CYCLOPHOSPHAMIDE OR GEMCITABINE FOR CHILDREN AND ADOLESCENTS WITH REFRACTORY OR RECURRENT MEDULLOBLASTOMA

Neuro-Oncology2024-06-182 citations

Evaluating the safety and effectiveness of PegaGen<sup>®</sup> (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study.

2022-07-061 citations

Highlights from Recent Cancer Literature

Cancer Research2021-04-01

Abstract 3031: Characterization of gemcitabine triphosphate formation in mice to aid in the development of a translational tumor model

Cancer Research2020-08-15

A randomized, multicenter clinical trial to determine the efficacy and safety of pegfilgrastim (GEMA BIOTECH) compared to pegfilgrastim (Roche) for prevention of chemotherapy induced neutropenia in patients with breast cancer.

Journal of Clinical Oncology2019-05-20

Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.

Journal of Clinical Oncology2017-05-206 citations